Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 6/2018

01-11-2018 | Original Article

Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study

Authors: Hsin-Yi Yang, Herng-Sheng Lee, Wan-Ting Huang, Ming-Jer Chen, Solomon Chih-Cheng Chen, Yueh-Han Hsu

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2018

Login to get access

Abstract

Polycystic ovary syndrome (PCOS) is a complex disorder; various features of this disorder may influence bone metabolism and skeletal mass. The contribution of PCOS to lower bone mineral density has been recognized. However, the impact of PCOS on the long-term risks for fractures remains inconclusive. The aim of this study was to determine the risk of overall fracture and fractures at different anatomic sites in patients with PCOS. Using a nationwide health insurance claims database, we included 11,106 subjects, aged 15–80 years, with newly diagnosed PCOS (ICD-9-CM: 254.4X) during 2000–2012. Patients with PCOS and respective age-matched (1:4) controls without PCOS were enrolled. The occurrence of fracture was monitored until the end of 2013. Cox regression and computed hazard ratios (HR) with 95% confidence intervals (95% CI) were used to determine the risk of PCOS among women with fractures. The PCOS and non-PCOS groups were comprised of 11,106 patients with PCOS and 44,424 participants without PCOS, respectively. Patients with PCOS had a higher incidence of any fractures compared with non-PCOS group (10.16 versus 8.07 per 1000 person-years) and a greater risk of any fractures [adjusted hazard ratio (aHR) = 1.23, 95% CI = 1.13–1.33], osteoporotic fractures (aHR = 1.33, 95% CI = 1.15–1.54), spine fractures (aHR = 1.36, 95% CI = 1.11–1.66) and forearm fractures (aHR = 1.39, 95% CI = 1.07–1.80), but the risk for femur or hip fracture, humerus, wrist and non-osteoporotic fractures were not increased. In conclusion, the PCOS group had a higher occurrence rate of fractures than the non-PCOS group. These results provide evidence for the adverse effects of PCOS on the risk of fractures.
Literature
1.
go back to reference Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S, Lin J, Zhu Y, Jiang Y, Feng HL, Qiao J (2013) Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod 28:2562–2569CrossRef Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S, Lin J, Zhu Y, Jiang Y, Feng HL, Qiao J (2013) Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod 28:2562–2569CrossRef
2.
3.
go back to reference March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:544–551CrossRef March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:544–551CrossRef
4.
go back to reference Sirmans SM, Pate KA (2013) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1–13CrossRef Sirmans SM, Pate KA (2013) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1–13CrossRef
5.
go back to reference Glintborg D, Andersen M (2010) An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 26:281–296CrossRef Glintborg D, Andersen M (2010) An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 26:281–296CrossRef
6.
go back to reference Berberoglu Z (2015) Insight into bone metabolism and skeletal mass in polycystic ovary syndrome. EMJ Repro Health 1:46–53 Berberoglu Z (2015) Insight into bone metabolism and skeletal mass in polycystic ovary syndrome. EMJ Repro Health 1:46–53
7.
go back to reference Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8:41CrossRef Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8:41CrossRef
8.
go back to reference Krishnan A, Muthusami S (2017) Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol 232:R99–R113CrossRef Krishnan A, Muthusami S (2017) Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol 232:R99–R113CrossRef
9.
go back to reference Dorte Glintborg APH, Andersen Marianne (2013) Bone mineral density and vitamin D in PCOS and hirsutism. Expert Rev Endocrinol Meta 8:449–459CrossRef Dorte Glintborg APH, Andersen Marianne (2013) Bone mineral density and vitamin D in PCOS and hirsutism. Expert Rev Endocrinol Meta 8:449–459CrossRef
10.
go back to reference Karadag C, Yoldemir T, Gogas Yavuz D (2017) Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients. Gynecol Endocrinol 33:234–237CrossRef Karadag C, Yoldemir T, Gogas Yavuz D (2017) Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients. Gynecol Endocrinol 33:234–237CrossRef
11.
go back to reference Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol 48:169–173CrossRef Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocrinol 48:169–173CrossRef
12.
go back to reference Yuksel O, Dokmetas HS, Topcu S, Erselcan T, Sencan M (2001) Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 19:257–262CrossRef Yuksel O, Dokmetas HS, Topcu S, Erselcan T, Sencan M (2001) Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 19:257–262CrossRef
13.
go back to reference Kirchengast S, Huber J (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16:1255–1260CrossRef Kirchengast S, Huber J (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16:1255–1260CrossRef
14.
go back to reference Moran LJ, Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD (2015) Steroidal contraceptive use is associated with lower bone mineral density in polycystic ovary syndrome. Endocrine 50:811–815CrossRef Moran LJ, Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD (2015) Steroidal contraceptive use is associated with lower bone mineral density in polycystic ovary syndrome. Endocrine 50:811–815CrossRef
15.
go back to reference Katulski K, Slawek S, Czyzyk A, Podfigurna-Stopa A, Paczkowska K, Ignaszak N, Podkowa N, Meczekalski B (2014) Bone mineral density in women with polycystic ovary syndrome. J Endocrinol Invest 37:1219–1224CrossRef Katulski K, Slawek S, Czyzyk A, Podfigurna-Stopa A, Paczkowska K, Ignaszak N, Podkowa N, Meczekalski B (2014) Bone mineral density in women with polycystic ovary syndrome. J Endocrinol Invest 37:1219–1224CrossRef
16.
go back to reference Rubin KH, Glintborg D, Nybo M, Andersen M, Abrahamsen B (2016) Fracture risk is decreased in women with polycystic ovary syndrome: a register-based and population-based cohort study. J Bone Miner Res 31:709–717CrossRef Rubin KH, Glintborg D, Nybo M, Andersen M, Abrahamsen B (2016) Fracture risk is decreased in women with polycystic ovary syndrome: a register-based and population-based cohort study. J Bone Miner Res 31:709–717CrossRef
17.
go back to reference Schmidt J, Dahlgren E, Brannstrom M, Landin-Wilhelmsen K (2012) Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome—a long-term follow-up study. Clin Endocrinol 77:207–214CrossRef Schmidt J, Dahlgren E, Brannstrom M, Landin-Wilhelmsen K (2012) Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome—a long-term follow-up study. Clin Endocrinol 77:207–214CrossRef
19.
go back to reference Pan ML, Chen LR, Tsao HM, Chen KH (2015) Relationship between polycystic ovarian syndrome and subsequent gestational diabetes mellitus: a nationwide population-based study. PLoS One 10:e0140544CrossRef Pan ML, Chen LR, Tsao HM, Chen KH (2015) Relationship between polycystic ovarian syndrome and subsequent gestational diabetes mellitus: a nationwide population-based study. PLoS One 10:e0140544CrossRef
20.
go back to reference Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRef Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRef
21.
go back to reference Lai SW, Liao KF, Lai HC, Tsai PY, Lin CL, Chen PC, Sung FC (2013) Risk of major osteoporotic fracture after cardiovascular disease: a population-based cohort study in Taiwan. J Epidemiol 23:109–114CrossRef Lai SW, Liao KF, Lai HC, Tsai PY, Lin CL, Chen PC, Sung FC (2013) Risk of major osteoporotic fracture after cardiovascular disease: a population-based cohort study in Taiwan. J Epidemiol 23:109–114CrossRef
22.
go back to reference Wallace WH, Kelsey TW (2004) Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 19:1612–1617CrossRef Wallace WH, Kelsey TW (2004) Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 19:1612–1617CrossRef
23.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef
24.
go back to reference Kassanos D, Trakakis E, Baltas CS, Papakonstantinou O, Simeonidis G, Salamalekis G, Grammatikakis I, Basios G, Labos G, Skarantavos G, Balanika A (2010) Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod 25:2107–2114CrossRef Kassanos D, Trakakis E, Baltas CS, Papakonstantinou O, Simeonidis G, Salamalekis G, Grammatikakis I, Basios G, Labos G, Skarantavos G, Balanika A (2010) Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod 25:2107–2114CrossRef
25.
go back to reference Khosla S, Riggs BL, Robb RA, Camp JJ, Achenbach SJ, Oberg AL, Rouleau PA, Melton LJ 3rd (2005) Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocr Metab 90:5096–5103CrossRef Khosla S, Riggs BL, Robb RA, Camp JJ, Achenbach SJ, Oberg AL, Rouleau PA, Melton LJ 3rd (2005) Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocr Metab 90:5096–5103CrossRef
26.
go back to reference Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221–1227CrossRef Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323:1221–1227CrossRef
27.
go back to reference Seifert-Klauss V, Prior JC (2010) Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010:845180CrossRef Seifert-Klauss V, Prior JC (2010) Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010:845180CrossRef
28.
go back to reference Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B (2009) Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 161:575–582CrossRef Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B (2009) Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 161:575–582CrossRef
29.
go back to reference Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S (2013) The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol 169:853–865CrossRef Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S (2013) The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol 169:853–865CrossRef
30.
go back to reference Muscogiuri GMJ, Mathieu C, Badenhoop K, Tamer G, Orio F, Vieth R, Mezza T, Colao A, Pittas A (2014) Vitamin D as a potential contributor in endocrine health 612 and disease. Eur J Endocrinol 171:R101–R110CrossRef Muscogiuri GMJ, Mathieu C, Badenhoop K, Tamer G, Orio F, Vieth R, Mezza T, Colao A, Pittas A (2014) Vitamin D as a potential contributor in endocrine health 612 and disease. Eur J Endocrinol 171:R101–R110CrossRef
31.
go back to reference Thomson RL, Spedding S, Buckley JD (2012) Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol 77:343–350CrossRef Thomson RL, Spedding S, Buckley JD (2012) Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol 77:343–350CrossRef
32.
go back to reference Carmina E, Lobo RA (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82:661–665CrossRef Carmina E, Lobo RA (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 82:661–665CrossRef
33.
go back to reference Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R (2003) Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18:721–727CrossRef Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R (2003) Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18:721–727CrossRef
34.
go back to reference Moran LJ, Misso ML, Wild RA, Norman RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Updat 16:347–363CrossRef Moran LJ, Misso ML, Wild RA, Norman RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Updat 16:347–363CrossRef
35.
go back to reference Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocr Metab 84:165–169PubMed Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocr Metab 84:165–169PubMed
36.
go back to reference Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL (2006) Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocr Metab 91:3404–3410CrossRef Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL (2006) Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocr Metab 91:3404–3410CrossRef
37.
go back to reference Strotmeyer ES, Cauley JA (2007) Diabetes mellitus, bone mineral density, and fracture risk. Curr Opin Endocrinol Diabetes Obes 14:429–435CrossRef Strotmeyer ES, Cauley JA (2007) Diabetes mellitus, bone mineral density, and fracture risk. Curr Opin Endocrinol Diabetes Obes 14:429–435CrossRef
38.
go back to reference Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg MC, Ensrud KE, Hillier TA, Cauley JA (2005) Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131–140CrossRef Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg MC, Ensrud KE, Hillier TA, Cauley JA (2005) Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131–140CrossRef
39.
go back to reference Melton LJ 3rd, Hartmann LC, Achenbach SJ, Atkinson EJ, Therneau TM, Khosla S (2012) Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res 27:1196–1205CrossRef Melton LJ 3rd, Hartmann LC, Achenbach SJ, Atkinson EJ, Therneau TM, Khosla S (2012) Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res 27:1196–1205CrossRef
40.
go back to reference Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the women’s health initiative observational study. Arch Intern Med 165:552–558CrossRef Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the women’s health initiative observational study. Arch Intern Med 165:552–558CrossRef
41.
go back to reference Court-Brown CM, Caesar B (2006) Epidemiology of adult fractures: a review. Injury 37:691–697CrossRef Court-Brown CM, Caesar B (2006) Epidemiology of adult fractures: a review. Injury 37:691–697CrossRef
42.
go back to reference Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS (2007) Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertil Steril 88:727–729CrossRef Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS (2007) Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertil Steril 88:727–729CrossRef
43.
go back to reference Hsu MI (2015) Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clin Exp Reprod Med 42:86–93CrossRef Hsu MI (2015) Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clin Exp Reprod Med 42:86–93CrossRef
44.
go back to reference Zhao Y, Qiao J (2013) Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids 78:755–760CrossRef Zhao Y, Qiao J (2013) Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids 78:755–760CrossRef
45.
go back to reference Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, Xu L, Chen Z (2007) Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett 28:807–810PubMed Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, Xu L, Chen Z (2007) Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett 28:807–810PubMed
46.
go back to reference Chen X, Yang D, Li L, Feng S, Wang L (2006) Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod 21:2027–2032CrossRef Chen X, Yang D, Li L, Feng S, Wang L (2006) Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod 21:2027–2032CrossRef
47.
go back to reference Wei HJ, Young R, Kuo IL, Liaw CM, Chiang HS, Yeh CY (2009) Prevalence of insulin resistance and determination of risk factors for glucose intolerance in polycystic ovary syndrome: a cross-sectional study of Chinese infertility patients. Fertil Steril 91:1864–1868CrossRef Wei HJ, Young R, Kuo IL, Liaw CM, Chiang HS, Yeh CY (2009) Prevalence of insulin resistance and determination of risk factors for glucose intolerance in polycystic ovary syndrome: a cross-sectional study of Chinese infertility patients. Fertil Steril 91:1864–1868CrossRef
Metadata
Title
Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study
Authors
Hsin-Yi Yang
Herng-Sheng Lee
Wan-Ting Huang
Ming-Jer Chen
Solomon Chih-Cheng Chen
Yueh-Han Hsu
Publication date
01-11-2018
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2018
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-017-0894-8

Other articles of this Issue 6/2018

Journal of Bone and Mineral Metabolism 6/2018 Go to the issue

Letter to the Editor

PCOS and bone fractures

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine